

سبكة المعلومات الجامعية

CLETTON TROUBLE STORY





تبيكة المعلومات الجامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الالكتروني والميكروفيلم



نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأفلام قد اعدت دون آية تغيرات



يب أن

تحفظ هذه الأفلام بعيداً عن الغبار في درجة حرارة من 15 - 20 منوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of 15 – 25c and relative humidity 20-40 %



ثبيكة المعلومات الجامعية





تبكة المعلومات الجامعية



الأصلية تالفة

CATECHOLAMINES AND OTHER BIOCHEMICAL PARAMETERS IN **CORMOTENSIVE AND HYPERTENSIVE EGYPTIANS**

Thesis

. In partial fulfillment of The Master Degree of Science in Biochemistry

Submitted By

Somaya Ahmed Hammad Awad

(B. Sc. in Biochemistry, 1992)

Supervised by

rof. Dr. Nadia Mohamed Abd-Allah Prof. Dr. Fayza Abd-El Hameed Hassan

Prof. of Biodyemistry Faculty of Science

Ain Shams University

Prof. of Clinical and Chemical Pathology

Faculty of Medicine Cairo University

Dr. Amr Youssef Esmat

Ass. Prof. of Biodyemistry Faculty of Science

Ain Shams University


Department of Biochemistry **Faculty of Science** Ain Shams University 2001

یسم الله الرحون الرحیم " و قبل رب زدنی علما "

> صدق الله العظيم طه (۱۱۲)

I declare that this thesis has been composed by myself and that the work of which it is a record has been done by myself. It has not been submitted for a degree at this or any other university.

Somaya Ahmed Hammad



Acknowledgement

First and foremost, I Thank ALMIGHTY ALLAH, the most beneficial, most merciful, without HIS graceful help this thesis would have not been accomplished.

I would like to express my deepest gratitude and appreciation to **Prof. Dr. Nadia Mohamed Abd-Allah**, Professor of Biochemistry, Faculty of Science, Ain Shams University, for her generous assistance, continuous encouragement throughout this study and great effort in revising this work.

Many thanks are also due to Prof. Dr. Fayza Abd-El Hameed Hassan, Professor of Clinical and Chemical Pathology, Faculty of medicine, Cairo University, for her suggestion of the point, sincere help, providing the laboratory facilities and continuous encouragement throughout this study.

I am also grateful to **Dr. Amr Youssef Esmat**, Assistant Professor of Biochemistry , Faculty of Science , Ain Shams University , for his sincere advise , valuable discussion and profound reading of the manuscript .

Special thanks are due to **Prof. Dr. Nermeen Salah**, Professor of Pediatrics and Director of the Diabetic Endocrine and Metabolic Pediatric Unit of Children New Hospital, Cairo University, for providing the blood samples of the selected cases.

Abstract

Catecholamines and other biochemical parameters in normotensive and hypertensive Egyptians

Somaya Ahmed Hammad

Much of the published reference range data for plasma catecholamines in healthy children are incomplete and often contradictory in normotensive adults . It is also reported that hypertension is recorded in 54% and 15% in patients with phaeochromocytoma and primary hyperaldosteronism, respectively, which suggested that the diagnostic criteria need to be reevaluated. The present study was undertaken to establish the normal upper reference limit (URL) for resting plasma norepinephrine (NE), epinephrine (E), plasma renin activity (PRA), serum aldosterone (Aldo) as well as the catecholamines metabolite urinary vanillylmandelic acid (VMA) concentrations in normal healthy subjects with variable ages (5-10, 11-15, 16-40 and 41-60 yr). The aim of the study is also extended to monitor the changes in the previous biochemical parameters in Egyptian hypertensives and three patients with phaeochromocytoma compared to age - matching control groups. Results obtained from this study revealed the URLs for plasma NE, E, PRA, serum Aldo and urinary VMA. The data accepted are more or less similar to previously reported values using the same methodology. In hypertensives, all the tested parameters were significantly increased. Uncomplicated essential hypertension is found to be closely associated with elevation in plasma NE than E levels especially in pubertals and adults. In phaeochromocytoma, the elevation in plasma catecholamines is more pronounced than the urinary VMA while serum Aldo and PRA are independent. In the present study, 11 statistically significant positive coefficient correlations between (SBP) or (DBP) and the different studied biochemical parameters are reported.

Key words: Hypertension – Phaeochromocytoma – Catecholamines – Urinary vanillylmandelic acid – Aldosterone – Plasma renin activity

Contents

List of Abbreviations	I
List of Figures	111
List of Tables	₹7T
Introduction	۷۱
Aim of the Work	IX
Aim of the Work	XII
Chapter I : Review of literature	
1 The adversal gland	
1. The adrenal gland 1.1. Histology of the adrenal gland	l
1.2. Embryology of the adrenal gland	
2. Catecholamines	5
2.1. Biosynthesis of catecholamines	7
2.2. Metabolism of catecholamines	9
3. Physiologic and Metabolic Effects of Adrenal Medullary	11
Hormones	
4. Blood Pressure	14
4.1. Arterial hypertension	15
4.2. Classification of hypertension	16
4.5. Regulation of blood pressure	17
4.3.1. Na'/ K'- ATP ase pump	19
4.3.2. Excitation-contraction coupling in vascular smooth muscle	21
5. Causes of Arterial Hypertension	20
5.1. The physiological (environmental) causes	28
5.1.1. Age	20
5.1.2. Obesity	28
5.1.3. Smoking	28
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake	28
5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes	282930
5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension	28 30 31
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors	28 30 31
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic pervous system hyperactivity and the	28 30 31
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catechologines effect	
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catecholamines effect 5.2.2. Causes for secondary hypertension	
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catecholamines effect 5.2.2. Causes for secondary hypertension 5.2.2.1. Insulin resistance	
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catecholamines effect 5.2.2. Causes for secondary hypertension 5.2.2.1. Insulin resistance 5.2.2.2. Estrogen use	
5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catecholamines effect 5.2.2. Causes for secondary hypertension 5.2.2.1. Insulin resistance 5.2.2.2. Estrogen use 5.2.2.3. Renal vascular disease	
5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catecholamines effect 5.2.2. Causes for secondary hypertension 5.2.2.1. Insulin resistance 5.2.2.2. Estrogen use 5.2.2.3. Renal vascular disease 5.2.2.4. Renal parenchymal disease	
5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catecholamines effect 5.2.2. Causes for secondary hypertension 5.2.2.1. Insulin resistance 5.2.2.2. Estrogen use 5.2.2.3. Renal vascular disease 5.2.2.4. Renal parenchymal disease 5.2.2.5. Vasopressin effect and vasodenressors deficiency	
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catecholamines effect 5.2.2. Causes for secondary hypertension 5.2.2.1. Insulin resistance 5.2.2.2. Estrogen use 5.2.2.3. Renal vascular disease 5.2.2.4. Renal parenchymal disease 5.2.2.5. Vasopressin effect and vasodepressors deficiency 5.2.2.6. Adrenal gland diseases	
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catecholamines effect 5.2.2. Causes for secondary hypertension 5.2.2.1. Insulin resistance 5.2.2.2. Estrogen use 5.2.2.3. Renal vascular disease 5.2.2.4. Renal parenchymal disease 5.2.2.5. Vasopressin effect and vasodepressors deficiency 5.2.2.6. Adrenal gland diseases Primary aldosteronism (Conn's syndrome)	
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catecholamines effect 5.2.2. Causes for secondary hypertension 5.2.2.1. Insulin resistance 5.2.2.2. Estrogen use 5.2.2.3. Renal vascular disease 5.2.2.4. Renal parenchymal disease 5.2.2.5. Vasopressin effect and vasodepressors deficiency 5.2.2.6. Adrenal gland diseases Primary aldosteronism (Conn's syndrome) Cushing's syndrome	
5.1.2. Obesity 5.1.3. Smoking 5.1.4. Salt intake 5.2. The pathological causes 5.2.1. Causes for primary (essential) hypertension 5.2.1.1. Genetic factors 5.2.1.2. Sympathetic nervous system hyperactivity and the catecholamines effect 5.2.2. Causes for secondary hypertension 5.2.2.1. Insulin resistance 5.2.2.2. Estrogen use 5.2.2.3. Renal vascular disease 5.2.2.4. Renal parenchymal disease 5.2.2.5. Vasopressin effect and vasodepressors deficiency 5.2.2.6. Adrenal gland diseases Primary aldosteronism (Conn's syndrome)	